Cysteine-Engineered Antibody Conjugates for Controlled DAR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional methods for generating antibody drug conjugates (ADCs) through conjugation via native cysteine or lysine residues result in heterogeneous mixtures, leading to issues with antibody stability, specificity, in vivo distribution, pharmacokinetics, and efficacy due to variability in drug load and conjugation sites.
Innovation Solution
Engineer cysteine insertion mutations at specific positions in the antibody structure to enable site-specific conjugation, allowing for the formation of cysteine engineered antibody constructs that can be conjugated with active agents, thereby controlling the drug-to-antibody ratio (DAR) and reducing heterogeneity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional conjugation via native cysteine or lysine residues is used, then the conjugation process is simple, but heterogeneous mixtures are produced leading to poor stability and efficacy
Solution Approach 1:
The patent introduces cysteine residues at specific local positions within the antibody structure (e.g., positions 239, 295, 300 in the heavy chain) to create site-specific conjugation capabilities. This local modification approach ensures that drugs are attached only at predetermined locations, producing homogeneous conjugates with consistent DAR values while maintaining controlled engineering complexity through targeted rather than global modifications.
2Manufacturing precision
If site-specific cysteine substitution is used, then conjugation homogeneity is improved, but antibody function may be compromised due to abolition of FcγR binding and ADCC
Solution Approach 1:
The patent systematically evaluates different cysteine insertion positions (positions 239, 295, 300 in the heavy chain) to find optimal parameters that balance conjugation homogeneity with preservation of antibody function. By changing the positional parameter of cysteine insertion and the surrounding amino acid sequence context, the patent achieves site-specific conjugation while maintaining FcγR binding and ADCC activities through careful sequence design and selection.
Data Source
AI summary
Antibody constructs engineered to introduce at least one cysteine insertion mutation (“cysteine engineered antibody constructs”) are described. The inserted cysteine residue(s) may be used as a site for conjugation of one or more active agents to the antibody construct to provide conjugates, such as antibody-drug conjugates.